Developer docs
API playgroundTry for free, no card

Search company profiles

Phytome Life Sciences

Full company profile

uuid000isn3

Namestring
Phytome Life Sciences
Websiteurl
phytomelife.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Phytome Life Sciences is a London, United Kingdom-based pharmaceutical company founded in 2018 by Sebastian Vaughan, who serves as Founder and CEO. The firm develops plant-derived biotherapeutics, with stated positioning toward addressing unmet medical needs. It operates as a privately held for-profit entity with a small team of 11-50 employees. The therapeutic hypothesis — using botanical sources as the basis for biologic drug candidates — places the company within the broader plant-derived pharma / phytopharmaceutical subsegment, a category that has produced approved products in specific indications but remains less established than synthetic biologics in mainstream pharma pipelines.

Publicly available information on the company is extremely limited. The company website (phytomelife.com) currently returns only a verification/loader page with no substantive content, and the firmographic and supplementary data sources contain no product portfolio, clinical pipeline details, funding history, partnerships, customer references, pricing, geographic footprint, certifications, intellectual property disclosures, or commercial activity. No management team beyond the founder is listed, no subsidiary or corporate structural history is recorded, and no investor disclosures or financial metrics are available. This data thinness prevents assessment of pipeline stage (whether the company is discovery, preclinical, or clinical), target indications, modality specifics (small molecules vs. complex biologics vs. extracts), regulatory milestones, capital base, or commercialization pathway.

Given the founder-led structure and small headcount over a five-plus-year operating history with no visible external capital or partnership events, the operating model most consistent with available evidence is a lean, internally funded early-stage research effort rather than a venture-backed, milestone-driven development program. Any deeper analysis of go-to-market, revenue mechanics, customer base, or competitive position requires primary-source diligence beyond the scope of available data.

Short descriptiontext

London-based pharmaceutical company founded in 2018 that develops plant-derived biotherapeutics for populations with unmet medical needs; privately held, founder-led (Sebastian Vaughan), with a small early-stage R&D team of 11-50 employees.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
plant-derived therapeutics, biopharmaceutical development, botanical drug discovery, plant-based medicines, biotherapeutic research
Industry1 code
PRIMARYAFADALAN
Phytogenics & Botanicals (Essential Oils, Herbs, Saponins)
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
Social media profiles2 records
Cost components4 values
Personnel, Technology or R&D, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Phytome Life Sciences is a pharmaceutical company developing plant-derived biotherapeutics targeted at poorly served patient populations. The company conducts discovery and development work to translate botanical materials into therapeutic drug candidates. It operates as a private London-based R&D entity founded in 2018.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Plant-derived biotherapeutic pipeline
CategoryBiopharmaceuticals
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

Clinical-stage company developing plant-derived cannabinoid medicines for chronic conditions. Similar botanical-pharma positioning, comparable team size, and parallel regulatory strategy.

TypeDirect peer
Description

Clinical-stage pharmaceutical company developing cannabinoid-based therapies, including proprietary manufacturing methods for plant-derived compounds. Closely comparable in scale, modality, and plant-based pipeline orientation.

3Botanix Pharmaceuticals
TypeDirect peer
Description

Focused on cannabis-derived pharmaceutical products, particularly in dermatology. Comparable in leveraging plant-derived APIs through clinical development and has reached Phase 2/3 readouts, illustrating a viable path to value.

TypeBroad incumbent
Description

Global biopharmaceutical company whose acquisition of GW Pharma validated the plant-derived therapeutic category. Represents the most likely strategic acquirer and a benchmark for the value ceiling of the category.

TypeOthers
Description

Non-profit R&D organization developing treatments for neglected diseases, often in partnership with smaller biotechs. Highly relevant ecosystem participant given Phytome's stated mission focus on therapeutics for poor and underserved populations.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing cannabinoid-derived therapeutics. Comparable in size, stage, and plant-derived therapeutic modality, with overlapping indications in oncology and inflammation.

TypeBroad incumbent
Description

Major pharmaceutical company with active programs in natural-product-derived therapeutics and global-health initiatives relevant to Phytome's underserved-patient mission. Potential partner or acquirer for late-stage assets.

TypeEmerging player
Description

Develops novel drug candidates derived from botanical sources for CNS and inflammatory diseases. Smaller and earlier-stage but comparable in the botanical-to-pharma transition thesis.

TypeDirect peer
Description

Pioneer of plant-derived cannabinoid therapeutics (Epidiolex), acquired by Jazz Pharmaceuticals for $7.2B. Most directly comparable peer — same plant-derived small-molecule therapeutic model, validated regulatory pathway, and global commercialization.

TypeDirect peer
Description

Pharmaceutical company developing CBD-based therapeutics using a proprietary delivery platform. Comparable in focusing exclusively on plant-derived pharmaceutical candidates, with clinical-stage assets in pain and inflammatory conditions.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phytome Life Sciences

Biopharmaceuticalsphytomelife.com

London-based pharmaceutical company founded in 2018 that develops plant-derived biotherapeutics for populations with unmet medical needs; privately held, founder-led (Sebastian Vaughan), with a small early-stage R&D team of 11-50 employees.

What Phytome Life Sciences does

Phytome Life Sciences is a London, United Kingdom-based pharmaceutical company founded in 2018 by Sebastian Vaughan, who serves as Founder and CEO. The firm develops plant-derived biotherapeutics, with stated positioning toward addressing unmet medical needs. It operates as a privately held for-profit entity with a small team of 11-50 employees. The therapeutic hypothesis — using botanical sources as the basis for biologic drug candidates — places the company within the broader plant-derived pharma / phytopharmaceutical subsegment, a category that has produced approved products in specific indications but remains less established than synthetic biologics in mainstream pharma pipelines.

Publicly available information on the company is extremely limited. The company website (phytomelife.com) currently returns only a verification/loader page with no substantive content, and the firmographic and supplementary data sources contain no product portfolio, clinical pipeline details, funding history, partnerships, customer references, pricing, geographic footprint, certifications, intellectual property disclosures, or commercial activity. No management team beyond the founder is listed, no subsidiary or corporate structural history is recorded, and no investor disclosures or financial metrics are available. This data thinness prevents assessment of pipeline stage (whether the company is discovery, preclinical, or clinical), target indications, modality specifics (small molecules vs. complex biologics vs. extracts), regulatory milestones, capital base, or commercialization pathway.

Given the founder-led structure and small headcount over a five-plus-year operating history with no visible external capital or partnership events, the operating model most consistent with available evidence is a lean, internally funded early-stage research effort rather than a venture-backed, milestone-driven development program. Any deeper analysis of go-to-market, revenue mechanics, customer base, or competitive position requires primary-source diligence beyond the scope of available data.

Phytome Life Sciences firmographics

Firmographics
Name
Phytome Life Sciences
Website
https://phytomelife.com
Company type
Private
Founded year
2018
Headcount range
11–50 employees
Short description
London-based pharmaceutical company founded in 2018 that develops plant-derived biotherapeutics for populations with unmet medical needs; privately held, founder-led (Sebastian Vaughan), with a small early-stage R&D team of 11-50 employees.
Ownership category
akta.pro rank

Phytome Life Sciences industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYAFADALAN
Phytogenics & Botanicals (Essential Oils, Herbs, Saponins)

Keywords

  • Plant-derived therapeutics
  • Biopharmaceutical development
  • Botanical drug discovery
  • Plant-based medicines
  • Biotherapeutic research

Where Phytome Life Sciences is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Markets served

Phytome Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain

Phytome Life Sciences product offering

Product offering

Core offering

Phytome Life Sciences is a pharmaceutical company developing plant-derived biotherapeutics targeted at poorly served patient populations. The company conducts discovery and development work to translate botanical materials into therapeutic drug candidates. It operates as a private London-based R&D entity founded in 2018.

Differentiator

Problem solved

Functional benefit

Products and services

  • Plant-derived biotherapeutic pipeline

Companies that use Phytome Life Sciences

Customer profile

Ideal customer profiles1 record

Phytome Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Phytome Life Sciences partnerships and signals

Strategic signal

Recent moves1 record

Phytome Life Sciences competitors and assessment

Company assessment

Direct peers

  • Zelira Therapeutics: Clinical-stage company developing plant-derived cannabinoid medicines for chronic conditions. Similar botanical-pharma positioning, comparable team size, and parallel regulatory strategy.
  • InMed Pharmaceuticals: Clinical-stage pharmaceutical company developing cannabinoid-based therapies, including proprietary manufacturing methods for plant-derived compounds. Closely comparable in scale, modality, and plant-based pipeline orientation.
  • Botanix Pharmaceuticals: Focused on cannabis-derived pharmaceutical products, particularly in dermatology. Comparable in leveraging plant-derived APIs through clinical development and has reached Phase 2/3 readouts, illustrating a viable path to value.
  • GW Pharmaceuticals (Jazz Pharmaceuticals): Pioneer of plant-derived cannabinoid therapeutics (Epidiolex), acquired by Jazz Pharmaceuticals for $7.2B. Most directly comparable peer — same plant-derived small-molecule therapeutic model, validated regulatory pathway, and global commercialization.
  • Ananda Scientific: Pharmaceutical company developing CBD-based therapeutics using a proprietary delivery platform. Comparable in focusing exclusively on plant-derived pharmaceutical candidates, with clinical-stage assets in pain and inflammatory conditions.

Broad incumbents

  • Jazz Pharmaceuticals: Global biopharmaceutical company whose acquisition of GW Pharma validated the plant-derived therapeutic category. Represents the most likely strategic acquirer and a benchmark for the value ceiling of the category.
  • Pfizer: Major pharmaceutical company with active programs in natural-product-derived therapeutics and global-health initiatives relevant to Phytome's underserved-patient mission. Potential partner or acquirer for late-stage assets.

Others

  • DNDi (Drugs for Neglected Diseases initiative): Non-profit R&D organization developing treatments for neglected diseases, often in partnership with smaller biotechs. Highly relevant ecosystem participant given Phytome's stated mission focus on therapeutics for poor and underserved populations.

Emerging players

  • Artelo Biosciences: Clinical-stage biopharmaceutical company developing cannabinoid-derived therapeutics. Comparable in size, stage, and plant-derived therapeutic modality, with overlapping indications in oncology and inflammation.
  • Emerald Health Pharmaceuticals: Develops novel drug candidates derived from botanical sources for CNS and inflammatory diseases. Smaller and earlier-stage but comparable in the botanical-to-pharma transition thesis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights5 records

Customer concentration

Phytome Life Sciences social profiles

Digital presence

Phytome Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phytome Life Sciences leadership team

Management profile

Number of profiles

Profiles1 record

Phytome Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phytome Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phytome Life Sciences

What does Phytome Life Sciences do?

Phytome Life Sciences is a pharmaceutical company developing plant-derived biotherapeutics targeted at poorly served patient populations. The company conducts discovery and development work to translate botanical materials into therapeutic drug candidates. It operates as a private London-based R&D entity founded in 2018.

When was Phytome Life Sciences founded?

Phytome Life Sciences was founded in 2018. It employs 11 to 50 people.

Where is Phytome Life Sciences based?

Phytome Life Sciences is headquartered in London, United Kingdom, in the Europe region.

Who are Phytome Life Sciences's main competitors?

Direct peers on record are Zelira Therapeutics, InMed Pharmaceuticals, Botanix Pharmaceuticals, GW Pharmaceuticals (Jazz Pharmaceuticals) and Ananda Scientific. Broad incumbents are Jazz Pharmaceuticals and Pfizer. DNDi (Drugs for Neglected Diseases initiative) is listed as an others. Emerging players are Artelo Biosciences and Emerald Health Pharmaceuticals.

Does Phytome Life Sciences have an API?

No public API is recorded for Phytome Life Sciences.

What industry is Phytome Life Sciences in?

Phytome Life Sciences's product category is Biopharmaceuticals. Its primary akta.pro industry code is AFADALAN, Phytogenics & Botanicals (Essential Oils, Herbs, Saponins). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales